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Abstract
Inhibitors of PI3K/Akt signaling are being actively developed for tumor therapy owing to the frequent mutational
activation of the PI3K-Akt-mTORC1 pathway inmany cancers, including glioblastomas (GBMs). NVP-BEZ235 is a novel
and potent dual PI3K/mTOR inhibitor that is currently in phase 1/2 clinical trials for advanced solid tumors. Here, we
show that NVP-BEZ235 also potently inhibits ATM and DNA-PKcs, the two major kinases responding to ionizing
radiation (IR)–induced DNA double-strand breaks (DSBs). Consequently, NVP-BEZ235 blocks both nonhomologous
end joining and homologous recombination DNA repair pathways resulting in significant attenuation of DSB repair.
In addition, phosphorylation of ATM targets and implementation of the G2/M cell cycle checkpoint are also attenuated
by this drug. As a result, NVP-BEZ235 confers an extreme degree of radiosensitization and impairs DSB repair in a
panel of GBM cell lines irrespective of their Akt activation status. NVP-BEZ235 also significantly impairs DSB repair in a
mouse tumor model thereby validating the efficacy of this drug as a DNA repair inhibitor in vivo. Our results, showing
that NVP-BEZ235 is a potent and novel inhibitor of ATM and DNA-PKcs, have important implications for the informed
and rational design of clinical trials involving this drug and also reveal the potential utility of NVP-BEZ235 as an effective
radiosensitizer for GBMs in the clinic.
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Introduction
The phosphatidylinositol 3-kinase (PI3K)–Akt-mTORC1 pathway is
frequently activated in a variety of human cancers, including glioblas-
tomas (GBMs). Therefore, inhibitors of PI3K/Akt signaling are being
actively developed for tumor therapy (reviewed in Liu et al. [1] and
Garcia-Echeverria and Sellers [2]). Dual PI3K-mTOR inhibitors are
particularly effective in blocking Akt activation because they prevent
the feedback activation of PI3K signaling normally observed with
mTORC1 inhibitors, such as rapamycin. NVP-BEZ235 is a potent
dual PI3K-mTOR inhibitor [3] that has shown great efficacy in inhib-
iting tumor growth in preclinical mouse models [4–11] and is cur-
rently being evaluated in phase 1/2 clinical trials for advanced solid
tumors (colorectal, breast, non–small cell lung carcinoma, renal, and
sarcoma; reviewed in Garcia-Echeverria and Sellers [2]). The design
of these trials is based on the premise that this compound specifically
inhibits PI3Ks [half-maximal inhibitory concentration (IC50) = 4-75 nM]
and mTOR (IC50 = 20 nM) with little cross-reactivity toward other
kinases, as previously reported [3]. However, mTOR belongs to the
PI3K-like kinase (PI3KK) family, which includes the two major ki-
nases that respond directly to DNA double-strand breaks (DSBs),
ATM and DNA-PKcs, both of which have catalytic domains highly
homologous to that of the PI3Ks [1,12]. Because DSBs are induced
during radiotherapy and commonly generated during chemotherapy,
it is particularly important to understand the effects of NVP-BEZ235
on these two kinases.
A number of recent reports identify an important role for the PI3K-
Akt pathway in radioresistance (reviewed in Mukherjee et al. [13] and
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Begg et al. [14]). Our laboratory and those of others have shown that
GBM-relevant cells and tumors with epidermal growth factor receptor
vIII (EGFRvIII) amplification or PTEN loss exhibit proficient DSB
repair, which confers radioresistance [15–19]. Because radiotherapy
plays a key role in the treatment of GBM, we investigated the poten-
tial utility of NVP-BEZ235 as a radiosensitizing agent against human
GBM lines. Surprisingly, we found that very low concentrations of
this drug conferred a high degree of radiosensitization that was signif-
icantly greater than that previously reported with PI3K/Akt inhibition
[15–19], and this correlated with attenuation of DSB repair. Detailed
experimentation revealed that NVP-BEZ235 potently inhibits ATM
and DNA-PKcs, thereby blocking both nonhomologous end joining
(NHEJ) and homologous recombination (HR), the two major path-
ways of DSB repair. In addition, phosphorylation of ATM targets and
implementation of the G2/M cell cycle checkpoint are also attenuated
by this drug. The consequence is profound radiosensitization at very
low concentrations of NVP-BEZ235 (100 nM). This radiosensitizing
effect is significantly more potent than that seen with much higher
concentrations (10 μm) of current inhibitors of DNA-PKcs [20] or
ATM [21] that are being optimized for clinical testing (reviewed in
Ding et al. [22]). These results have significant translational impor-
tance, both for the design of current clinical trials involving this drug
and for the potential use of this drug as a powerful radiosensitizer in
the clinic.
Materials and Methods
Cell Culture and Drug Treatment
The cell lines used in this study are U251, U118, LN18, T98G,
LN229, SF188, 1BR3, AT5, M059K, and M059J. The U87 glioma
line expressing EGFRvIII has been described before [19]. All cell lines
were maintained in Dulbecco modified Eagle medium containing 10%
fetal bovine serum in a humidified 37°C incubator with 5% CO2. All
cells wereMycoplasma free. NVP-BEZ235 (Selleck Chemicals, Houston,
TX),NU7026 (Sigma, St Louis,MO), andKU55933 (EMDChemicals,
Darmstadt, Germany) were dissolved in dimethyl sulfoxide (DMSO), and
10-mM stocks were stored at −20°C. Cells were treated with drugs for
1 hour before irradiation.
Irradiation of Cells
Cells were irradiated with gamma rays from a 137Cs source ( JL
Shepherd and Associates, CA) at the indicated doses. Subcutaneous
tumors in mice were irradiated with an x-ray device (X-RAD 320,
Precision X-ray, North Branford, CT; 300 kV, 12 mA, 1.65 mm Al)
fitted with a specifically designed collimator providing a 1-cm-diameter
field size iso-dose exposure. For laser irradiation, cells were microirra-
diated with a pulsed nitrogen laser (Spectra-Physics, Newport Corpo-
ration, Santa Clara, CA; 365 nm, 10 Hz) with output set at 75% of the
maximum, as described [23].
Western Analyses and Immunof luorescence Staining
For Western blot analysis of ATM and DNA-PKcs, nuclear extracts
were prepared as described [24]. For Western blot analysis of all other
proteins, whole-cell extracts were prepared as described [25]. Western
blot analysis was carried out as described [24]. Immunofluorescence
(IF) staining of cells and tumor sections was performed as described
[19]. Antibodies used were as follows: anti–phospho-Akt(S473), anti-
Akt, anti–phospho-Chk2(T68), anti–phospho-p53(S15), and anti–
phospho-S6(S235/236) (Cell Signaling, Danvers, MA); anti-actin
and anti-ATM (Sigma); anti-Rad51, anti–cyclin A, anti-p53, and
anti-53BP1 (Santa Cruz, Biotechnology, Santa Cruz, CA); anti–phospho-
SMC1(S966), anti-SMC1, anti–phospho-KAP-1(S824), anti–KAP-1,
anti-Chk2, and anti-H2AX (Bethyl Laboratories, Montgomery, TX );
anti-γH2AX and pHistone-H3(S10) (Upstate, Billerica, MA); anti–
phospho-ATM(S1981) (GenScript, Piscataway, NJ); anti–phospho-
DNA-PKcs (S2056) (Abcam, Cambridge, MA); anti–DNA-PKcs
(ThermoFisher,Waltham,MA); anti-Ku80 (kind gift fromDr. B. Chen);
HRP-conjugated secondary antibodies (Biorad, Hercules, CA); and
Alexa488/568–conjugated secondary antibodies (Molecular Probes,
Grand Island, NY). Primary antibodies were incubated overnight at
4°C, and secondary antibodies were incubated for 1 hour at room tem-
perature for both IF and Western blot analysis. Antibody dilutions are
provided in Table W1.
Colony Formation Assays
Cells were plated in triplicate onto 60-mm dishes (1000 cells per dish),
treated with the indicated drugs, and irradiated 1 hour later with graded
doses of radiation. At 16 hours after irradiation, drug-containing medium
was replaced with drug-free medium. Surviving colonies were stained
with crystal violet approximately 10 to 14 days later as described [19].
DSB Repair Assays
DSB repair rates were assessed by quantifying the rates of dissolu-
tion of 53BP1 foci after irradiation of cells with 1 Gy of gamma rays
as described [19]. For quantifying Rad51 foci, cells were irradiated
with 6 Gy of gamma rays and coimmunostained with Rad51 and
cyclin A antibodies 3 hours later as described [23]. The average numbers
of Rad51 foci for cyclin A–positive (S/G2) nuclei were determined after
scoring at least 50 nuclei.
HR and NHEJ Assays
In the HR assay, GFP expression was quantified (by flow cytometry)
in MCF7-DRGFP cells transfected with an I-SceI plasmid as described
[26]. In the NHEJ assay, repair of site-specific I-SceI–induced breaks in
engineered 293T cells by NHEJ results in the conversion of a GFP
signal to RFP (quantified by flow cytometry) as described [27].
G2/M Checkpoint Assay
The G2/M checkpoint was evaluated by quantifying histone H3
phosphorylation by flow cytometry as described [23].
DNA-PKcs Kinase Assays
In vitro kinase assays were carried out with purified DNA-PKcs
(Invitrogen, Grand Island, NY) usingGST-p53 (Santa Cruz) as substrate
as described [28]. Sheared herring testis DNA (Clontech, Mountain
View, CA) was added to the DNA-PKcs kinase assays to stimulate ki-
nase activity.
Mouse Tumor Studies
Tumors were generated by subcutaneous injection of U87 cells
overexpressing EGFRvIII [19] into 6-week-old female Nu/Nu mice.
Once these tumors reached an average size of 150 mm3, mice were
treated with a single dose of 45 mg/kg NVP-BEZ235 by oral gavage
or with vehicle (NMP/polyethylene glycol 300; 10:9 vol/vol) as con-
trol. Two hours later, tumors were irradiated with 2 Gy of x-rays,
and tumors were excised at the indicated time points. All animal studies
were performed under protocols approved by the Institutional Animal
Care and Use Committee of UT Southwestern Medical Center.
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Statistical Analyses
Statistical significance was determined by a 2-tailed t test using
GraphPad Prism software (San Diego, CA; **P < .01, ***P < .001).
Error bars represent the SEM for all plots.
Results
Because PI3K-Akt signaling has been shown to promote DSB repair
in GBM cells and tumors [15–19], we assessed whether NVP-
BEZ235 could radiosensitize human GBM cells by inhibiting DNA
repair. We chose a panel of six GBM lines, of which four (U251,
U118, LN18 and T98G) exhibit high levels of activation of the
PI3K-Akt pathway as evidenced by high levels of Akt phosphorylation
(Ser473), whereas two (SF188 and LN229) exhibit lower levels of
Akt activation (Figure 1A). Radiation survival was measured by the
colony formation assay. We chose a concentration of 100 nM NVP-
BEZ235 for colony survival assays because this was the highest dose
at which plating efficiency was largely unaffected for most cell lines
(Table W2). We observed significant attenuation of Akt signaling with
NVP-BEZ235 treatment at 100 nM, in accord with previous reports
[3,5,6,8,11] (Figure 1A). We tested the radiosensitizing potential
of NVP-BEZ235 (100 nM) compared with the established radiosensi-
tizers and DNA repair inhibitors KU55933 (ATM inhibitor, 10 μM)
[21] and NU7026 (DNA-PKcs inhibitor, 10 μM) [20]. We found that
NVP-BEZ235 elicited a significantly greater degree of radiosensi-
tization compared with KU55933 or NU7026, and this was consis-
tent among all cell lines irrespective of their Akt activation status
(Figure 1B). Radiosensitization was drug dose dependent with a lesser
degree of sensitization seen with lower concentrations of NVP-BEZ235
(Figure W1). As indicated by IF staining for 53BP1 foci [19]
(Figure 1C), all glioma lines could complete DSB repair by 24 hours
after irradiation. However, NVP-BEZ235–treated cells showed higher
numbers of unresolved foci at 24 hours (Figure 1D), which correlates
with the high degree of radiosensitization observed.
Because the effect of NVP-BEZ235 onDSB repair and radioresistance
was significantly greater than what has been previously observed due to
inactivation of PI3K-Akt signaling [15–19], we hypothesized that this
compound might be inhibiting other kinases in addition to PI3K and
mTOR. The most likely candidates, given the striking inhibition of
DSB repair, are the DSB-responsive kinases, ATM and DNA-PKcs,
whose catalytic domains are highly homologous to that of PI3K and
mTOR [1,12]. We therefore examined the effects of NVP-BEZ235
in wild-type (1BR3) and ATM-deficient (AT5) human fibroblasts
[23] as well as in DNA-PKcs–proficient (MO59K) and –deficient
(MO59J) human glioma lines [29]. We found that NVP-BEZ235
could sensitize 1BR3 cells to IR, and the degree of sensitization was
significantly greater than that seen with KU55933 or NU7026
(Figure 2A). As expected, NU7026 and KU55933 treatments resulted
in attenuated DSB repair, consistent with the role of DNA-PKcs in
NHEJ [30] and the role of ATM in promoting HR [31] and hetero-
chromatic DSB repair [32] (Figure 2B). Strikingly, NVP-BEZ235
treatment resulted in a repair defect that was much more severe than
that seen with either NU7026 or KU55933 and affected both “early”
and “late” phases of DSB repair [32], with almost 70% of breaks
remaining unrepaired at 24 hours after irradiation.
These data suggest that the profound radiosensitization conferred
by NVP-BEZ235 is due to the inhibition of more than one DNA
repair pathway. Indeed, we found that NVP-BEZ235 could further
radiosensitize ATM-null [23] and DNA-PKcs-null [29] cell lines, in-
dicating that the radiosensitizing effect of the drug was not due to its
effect on just one PI3KK i.e., either ATM or DNA-PKcs (Figure 2,
C and D). Similarly, the DSB repair defects of both lines could be
further exacerbated after NVP-BEZ235 treatment (Figure 2, C and
D), clearly indicating that this compound can block multiple PI3KK
family members.
Among the PI3KK family members, ATM plays a central role in
the mammalian DNA damage response (DDR), triggering cell cycle
arrest and promoting DSB repair [33]. To examine if NVP-BEZ235
attenuates the activation of ATM, we irradiated 1BR3 cells and ana-
lyzed the autophosphorylation of ATM at Ser1981 by Western blot
analysis [35]. We found that NVP-BEZ235 attenuated IR-induced
activation of ATM, similar to the specific ATM inhibitor KU55933
(Figure 3A, top panel ). Moreover, autophosphorylation of ATM at
the sites of micro-laser-induced DSBs [23] was reduced by NVP-
BEZ235 pretreatment (Figure 3A, bottom panel). We irradiated
1BR3 cells after pretreatment with NVP-BEZ235 and, byWestern blot
analysis with phospho-specific antibodies as described [23], assessed the
phosphorylation status of the following key ATM substrates: Chk2
(Thr68), SMC1 (Ser966), p53 (Ser15), KAP-1 (Ser824), and H2AX
(Ser139). Phosphorylation of all of these ATM substrates was attenu-
ated (to varying extents) by pretreatment with NVP-BEZ235, similar
to that seen with KU55933 (Figure 3B). We validated the biologic
significance of this inhibition by examining the G2/M cell cycle check-
point in 1BR3 cells as described [23]. The G2/M block manifests as a
decrease in M-phase cells at 2 hours after irradiation, and this was
attenuated by NVP-BEZ235 to the same extent seen with KU55933
(Figure 3C). In addition to checkpoint signaling, ATM plays an impor-
tant role in DSB repair by HR in S/G2 phases [34]. Consistent with
inhibition of HR, we found that IR-induced Rad51 foci formation was
attenuated in 1BR3 cells pretreated with NVP-BEZ235 similar to that
seen with KU555933 treatment (Figure 3D, top panel ). Abrogation of
HR by NVP-BEZ235 was also seen in a GFP-based assay, which mea-
sures reconstitution of a GFP gene by HR after the induction of DSBs
by I-SceI [26] (Figure 3D, bottom panel ). These results indicate that
NVP-BEZ235 inhibits ATM activation, ATM-mediated phosphorylation
events, cell cycle checkpoints, and HR.
Apart from ATM, the other PI3KK family member that responds
directly to DSBs is DNA-PKs, a key enzyme in the NHEJ pathway
of DSB repair [30]. To investigate whether NVP-BEZ235 also inhibits
the activation of DNA-PKcs, we irradiated 1BR3 cells and examined
DNA-PKcs autophosphorylation at Ser2056 by Western blot analysis
[35]. We found that NVP-BEZ235 attenuated IR-induced activation
of DNA-PKcs, similar to the specific DNA-PKcs inhibitor NU7026
(Figure 4A, top panel ). Similarly, autophosphorylation of DNA-PKcs
at the sites of micro-laser-induced DSBs [23] was impaired on NVP-
BEZ235 pretreatment (Figure 4A, bottom panel ). To determine whether
NVP-BEZ235 can directly block DNA-PKcs kinase activity, we carried
out in vitro kinase assays with purified DNA-PKcs using GST-p53
(1-393) as a substrate [28]. DNA-PKcs efficiently phosphorylated p53
at Ser15 in vitro, and this was attenuated by NVP-BEZ235, indicating
that NVP-BEZ235 can directly block DNA-PKcs, similar to NU7026
(Figure 4B). Because DNA-PKcs is a key enzyme in the NHEJ pathway
of DSB repair [30], we used a GFP to RFP-conversion assay to inves-
tigate if NVP-BEZ235 might block NHEJ in addition to attenuating
HR [27]. We found that NVP-BEZ235 could potently block NHEJ
(no RFP signal after transfection with an I-SceI–expressing plasmid)
(Figure 4C ). These results clearly indicate that NVP-BEZ235 potently
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Figure 1. The dual PI3K/mTOR inhibitor NVP-BEZ235 potently impairs DSB repair and confers significant radiosensitization in a panel of
human GBM lines. (A) Inhibition of PI3K/Akt signaling in mock-irradiated or irradiated human GBM lines after treatment with 100 nM
NVP-BEZ235 was analyzed by Western blot analysis with α–phospho-Akt (Ser473) antibody. Cells were irradiated (10 Gy) after 1 hour of
drug treatment and harvested at 30 minutes after IR. (B) Radiation survival of GBM lines after treatment with the indicated concentra-
tions of NVP-BEZ235 (PI3K/mTOR inhibitor), KU55933 (ATM inhibitor), NU7026 (DNA-PKcs inhibitor), or DMSO (solvent) was quantified
by colony formation assays. The fraction of surviving colonies (y axis) was plotted against corresponding radiation dose (x axis). (C) GBM
cells were irradiated with 1 Gy of gamma rays after a 1-hour period of drug treatment. Cells were immunostained for 53BP1 foci (green)
at 0.5 and 24 hours after IR. Nuclei were stained with DAPI (blue). Representative pictures are shown for DMSO- or NVP-BEZ235–treated
U251 cells. (D) 53BP1 foci were scored at 0.5 and 24 hours after IR (average of 50 nuclei), and after subtracting background (number of
foci in mock-irradiated nuclei), the average foci per nucleus was plotted against the indicated times.
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blocks both ATM and DNA-PKcs, resulting in a DSB repair defect
that is more striking than that seen on the inhibition of ATM or
DNA-PKcs alone. Indeed, blocking both ATM and DNA-PKcs by
combining KU55933 and NU7026 resulted in greater numbers of
unrepaired DSBs, similar to that seen with NVP-BEZ235 alone, both
in 1BR3 cells (Figure 4D) as well as in the panel of GBM cell lines
(Figure W2). Given the potential cross-talk between ATM and
DNA-PKcs [36], we investigated whether NVP-BEZ235 could atten-
uate IR-induced ATM activation in DNA-PKcs-null M059J cells and
DNA-PKcs activation in ATM-null AT5 cells. We found inhibition of
kinase activation in both cell lines, demonstrating that this drug can
independently block either kinase (Figure W3). We also examined
ATM and DNA-PKcs activation in the panel of glioma lines that were
radiosensitized by NVP-BEZ235 (Figure 1B) and observed inhibition
of both ATM (Figure W4) and DNA-PKcs (Figure W5) to varying
extents. Taken together, these data implicate the impairment of both
HR and NHEJ repair pathways, due to inhibition of both ATM and
DNA-PKcs, as the underlying mechanism behind the profound radio-
sensitization conferred by NVP-BEZ235.
Finally, to examine the effect of NVP-BEZ235 on DSB repair in
tumors, we generated subcutaneous tumors in Nu/Nu mice using
U87 cells overexpressing EGFRvIII [19]. We first confirmed that
Figure 2. NVP-BEZ235 impairs both “early” and “late” phases of DSB repair and can exacerbate the repair defects of ATM- and DNA-
PKcs-null cells. (A) Radiation survival of wild-type 1BR3 fibroblasts on treatment with the indicated concentrations of NVP-BEZ235,
KU55933, NU7026, or DMSO was quantified by colony formation assays. The fraction of surviving colonies (y axis) was plotted against
the corresponding radiation dose (x axis). Inhibition of PI3K/Akt signaling after NVP-BEZ235 treatment for 1 hour or 16 hours was ana-
lyzed byWestern blot analysis with α–phospho-Akt (Ser473) antibody. (B) DSB repair kinetics of 1BR3 cells irradiated with 1 Gy of gamma
rays after a 1-hour period of drug treatment. Cells were immunostained for 53BP1 foci (green), and nuclei were stained with DAPI (blue).
Representative pictures are shown for DMSO- or NVP-BEZ235–treated 1BR3 cells. 53BP1 foci were scored at the indicated times after IR,
and percentage foci remaining was plotted against time. (C) Radiation sensitivity and DSB repair kinetics of ATM-deficient AT5 cells on
treatment with NVP-BEZ235. (D) Radiation sensitivity and DSB repair kinetics of DNA-PKcs–proficient (M059K) and –deficient (M059J)
cells on treatment with NVP-BEZ235.
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Figure 3. NVP-BEZ235 impairs ATM activation, phosphorylation of ATM substrates, G2/M cell cycle checkpoint, and HR repair. (A) Top
panel. 1BR3 cells were pretreated with the indicated concentrations of NVP-BEZ235 or KU55933 and irradiated with 10 Gy of gamma
rays. Autophosphorylation of ATM was assayed after 30 minutes by Western blot analysis with a α–phospho-ATM (Ser1981) antibody.
Bottom panel. 1BR3 cells, pretreated with DMSO or NVP-BEZ235, were laser microirradiated and co-IF stained with α–phospho-ATM
(Ser1981) antibody (red) and α-53BP1 antibody (green) after 30 minutes. (B) 1BR3 cells were pretreated for 1 hour with the indicated
concentrations of NVP-BEZ235 or KU55933 and irradiated with 10 Gy of gamma rays. Phosphorylation of key DDR proteins was assayed
after 30 minutes by Western blot analysis with phospho-specific antibodies as indicated. (C) IR-induced G2/M checkpoint in 1BR3 cells
treated with NVP-BEZ235 or KU55933 was analyzed by dual-parameter flow cytometry. Representative distributions show staining for DNA
content (x axis) and for histone H3 phosphorylation (y axis); cells in M phase are demarcated with blue circles. Percent cells in M-phase in
mock-irradiated and irradiated (4 Gy) cells are plotted. The G2/M checkpoint manifests as a decrease in mitotic cells at 2 hours after irradi-
ation in DMSO-treated cells; this decrease is not seen in NVP-BEZ235– or KU55933-treated cells. (D) Top panel. Representative image of
gamma-irradiated 1BR3 cells costained with α–cyclin A antibody (red) and α-Rad51 antibody (green) after 3 hours. Nuclei are stained with
DAPI (blue). Average numbers of Rad51 foci for cyclin A–positive (S/G2) nuclei at 3 hours after irradiation are plotted for 1BR cells pretreated
with NVP-BEZ235 or KU55933. Bottom panel. HR was measured by quantifying GFP expression (by flow cytometry) in MCF7-DRGFP cells
transfected with an I-SceI plasmid in the presence of NVP-BEZ235 or KU55933 as indicated. Plots show percentages of drug-treated cells
expressing GFP relative to DMSO-treated cells. GFP expression after transfection with a control plasmid with full-length GFPwas quantified
to ensure that transfection efficiencies were comparable between the different drug treatments.
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NVP-BEZ235 could inhibit Akt activation and block DSB repair in
U87-EGFRvIII cells in culture (Figure W6). Next, tumor-bearing
mice were treated with a single dose of 45 mg/kg NVP-BEZ235 or
with vehicle as control. Tumors were mock irradiated or irradiated
(2 Gy of x-rays) 2 hours later, collected at 0.5 and 24 hours after
IR, and sectioned for IF. Tumors from NVP-BEZ235–treated mice
exhibited a marked reduction in the phosphorylation of Akt (Ser473)
and abrogation of phosphorylation of an mTOR substrate, the ribo-
somal protein S6 (Ser235/236), thereby confirming intratumoral
delivery of the drug and consequent inhibition of the PI3K-Akt-
mTOR pathway [7] (Figure 5A). Irradiated NVP-BEZ235– or vehicle-
treated tumor sections were IF stained for 53BP1 foci as described [19].
Vehicle-treated tumors were able to completely repair radiation-induced
DSBs by 24 hours after IR. Interestingly, NVP-BEZ235–treated tumors
exhibited higher levels of unresolved 53BP1 foci at 24 hours after IR,
indicating attenuation of DSB repair (Figure 5, B and C). These results
unequivocally demonstrate that the striking inhibition of DSB repair by
NVP-BEZ235 is also valid in a tumor setting.
Figure 4. NVP-BEZ235 impairs DNA-PKcs activation and NHEJ. (A) Top panel. 1BR3 cells were pretreated with NVP-BEZ235 or NU7026
and irradiated with 10 Gy of gamma rays. Autophosphorylation of DNA-PKcs was assayed after 30 minutes by Western blot analysis with
a α–phospho-DNA-PKcs (Ser2056) antibody. Bottom panel. 1BR3 cells, pretreated with DMSO or NVP-BEZ235, were laser microirradiated
and co-IF stained with α–phospho-DNA-PKcs (Ser2056) antibody (green) and α-γH2AX antibody (red) after 30 minutes. (B) In vitro kinase
assays were carried out with purified DNA-PKcs incubated with recombinant GST-p53 (1-393) in the presence of sheared herring testis
DNA and ATP. Increasing concentrations of NVP-BEZ235 or NU7026 were added to the reaction mixture as indicated. Phosphorylation of
p53 by DNA-PKcs was assessed by Western blot analysis with α–phospho-p53 (Ser15) antibody. (C) The NHEJ assay was initiated by the
transfection of an I-SceI plasmid into engineered 293T cells harboring a GFP gene (flanked by I-SceI sites) followed by a RFP gene. A
switch from GFP to RFP expression indicates ligation of I-SceI–generated breaks by NHEJ. Representative distributions show RFP +ve
cells (red circles) and GFP +ve cells (green circles) for different drug treatments; percentages of RFP +ve cells are indicated and are plotted
for cells treated with increasing concentrations of NVP-BEZ235 or NU7026. (D) 1BR3 cells were irradiated with 1 Gy of gamma rays after
a 1-hour period of treatment with NVP-BEZ235, KU55933, or NU7026 alone or with a combination of KU55933 and NU7026, as indicated. To
quantify residual (unrepaired) DSBs, cells were immunostained for 53BP1 foci at 24 hours after IR. Residual 53BP1 foci in irradiated cells
were scored (average of 50 nuclei), and after subtracting background (number of foci in mock-irradiated nuclei), average foci per nucleus
were plotted against the indicated treatment conditions.
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Discussion
Using multiple approaches, we find that NVP-BEZ235, a drug already
in clinical trials, can inhibit IR-induced activation of ATM and DNA-
PKcs, the two major kinases responding to DSBs. This results in inhi-
bition of DSB repair, attenuation of cell cycle arrest, and profound
radio sensitization. In the original report describing the compound,
the authors examined the effects of NVP-BEZ235 only on doxorubicin-
induced phosphorylation of ATM (Ser1981) andDNA-PKcs (Thr2609)
and found attenuation only at high concentrations of the drug (1250 nm);
no other end points were analyzed, and it was inferred that the compound
has no cross-reactivity toward these two kinases [3]. However, we ob-
serve attenuation of ATM (Ser1981) and DNA-PKcs (Ser2056) auto-
phosphorylations at low concentrations (100 nM) of NVP-BEZ235.
Differences in cell lines, phospho-specific antibodies, DNA-damaging
agents, and duration of incubation with drugs probably underlie these
discrepancies. It is also important to point out that, as DNA-PKcs is
phosphorylated at Thr2609 by ATM, Ser2056 autophosphorylation
might be a better indicator of DNA-PKcs activity in vivo [36]. Regardless
of the extent of inhibition of ATM and DNA-PKcs autophosphoryla-
tion, our results clearly show that a low concentration of NVP-BEZ235
is sufficient to block key DDR events triggered by ATM and DNA-
PKcs — phosphorylation of DDR proteins, implementation of cell
cycle checkpoints, and repair of IR-induced DSBs by HR and NHEJ.
Moreover, we show that NVP-BEZ235 inhibits purified DNA-PKcs
in vitro indicating that the observed effects of NVP-BEZ235 are likely
due to a direct blockage of the kinase activity of this protein.
Cross-inhibition of ATM and DNA-PKcs by a dual PI3K-mTOR
inhibitor is not surprising because these kinases have homologous
catalytic domains [1,12]. In accord with our results, a previous report
demonstrated that NVP-BEZ235 could radiosensitize non–small cell
lung carcinoma cells expressing oncogenic K-RAS and this correlated
with higher levels of IR-induced DNA breaks, although the underly-
ing mechanism(s) were not investigated [8]. Also, an earlier report
demonstrated inhibition of DNA-PKcs kinase activity by NVP-
BEZ235 in vitro, although the radiosensitizing effect of this drug
was not tested in this study [37]. At the time this article was in prep-
aration, NVP-BEZ235 was shown to induce senescence in irradiated
cancer cells by inhibiting DNA-PKcs thereby supporting our data
showing radiosensitization by this drug due to inhibition of both
ATM and DNA-PKcs [38]. Moreover, NVP-BEZ235 was recently
identified in a cell-based screen as a potent ATR inhibitor [39]. Like
ATM and DNA-PKcs, ATR also belongs to the PI3KK family and
responds to ssDNA generated by the stalling of replication forks or
by the resection of DSBs [12]. Our findings, in combination with these
reports, unequivocally demonstrate that NVP-BEZ235 is a potent in-
hibitor of all members of the PI3KK family that respond to IR-induced
DNA breaks, either directly (ATM and DNA-PKcs) or indirectly
(ATR), resulting in profound radiosensitization at low concentrations
of the drug.
Figure 5. NVP-BEZ235 impairs the repair of IR-induced DNA dam-
age in tumors. (A) Nu/Nu mice bearing subcutaneous tumors
(U87-EGFRvIII) were treated with NVP-BEZ235 (45 mg/kg) or vehicle
alone and tumors were irradiated (2 Gy) 2 hours after drug treatment.
Tumors were collected at 0.5 or 24 hours after IR and sectioned for
IF staining. Tumor sections were stained for phosphorylation of Akt
(Ser473) and ribosomal protein S6 (Ser235/236) to confirm intra-
tumoral drug delivery and consequent inhibition of the PI3K-Akt-
mTOR pathway. (B) Tumor sections were IF stained for 53BP1 foci
(green) to visualize radiation-induced DSBs (at 0.5 hours) and resid-
ual breaks (at 24 hours). Representative pictures are shown for NVP-
BEZ235– or vehicle-treated tumors. (C) 53BP1 foci were scored at
0.5 and 24 hours after IR (average of 50 nuclei), and after subtracting
background (average number of foci in mock-irradiated tumors),
average foci per nucleus were plotted against the indicated times.
Please note residual 53BP1 foci in NVP-BEZ235–treated tumors,
confirming that the impairment of DSB repair by NVP-BEZ235 is also
valid in a tumor setting.
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Our study not only shows that NVP-BEZ235 is a novel inhibitor
of both ATM and DNA-PKcs but also establishes that this drug is
significantly more potent than specific inhibitors of ATM and DNA-
PKcs that are being optimized for use as radiosensitizers in the clinic
[22]. A very high degree of radiosensitization was seen with 100-fold
lower concentrations of NVP-BEZ235 (100 nM) relative to KU55933
(10 μM) or NU7026 (10 μM). Indeed, radiosensitization by NVP-
BEZ235 was greater than the higher degree of sensitization achieved
by combining both ATM and DNA-PKcs inhibitors (data not shown),
indicating that radiosensitization by NVP-BEZ235 is not just due to
combined inhibition of both DSB-responsive kinases. Thus, the ex-
treme radiosensitivity conferred by NVP-BEZ235 is clearly a combina-
torial effect of disabling multiple pathways impinging on 1) DSB repair
(due to DNA-PKcs and ATM inhibition), 2) cell cycle checkpoints
(due to ATM and ATR inhibition), and 3) cell survival (due to PI3K
and mTOR inhibition). These results have two important clinical
implications. On one hand, considering the significant impairment
of DDRs resulting from NVP-BEZ235 treatment, combining the drug
with genotoxic chemotherapy could result in significant systemic toxic-
ity and limit therapeutic gain. On the other hand, radiotherapy, like
surgery, is a local treatment and its efficacy could be significantly en-
hanced by the use of potent radiosensitizers like NVP-BEZ235, which
confers radiosensitization even at radiation doses used in conventional
fractionation schemes (1.8-2 Gy per fraction). Thus, highly conformal
techniques, such as intensity-modulated radiotherapy, might be able to
exploit the radiosensitizing potential of the drug while minimizing nor-
mal tissue toxicity. Current inhibitors of DNA-PKcs or ATM have not
yet reached clinical trials; however, NVP-BEZ235 is approved for phase
1/2 trials, and some preliminary clinical data already exist showing that
the drug is well tolerated [40]. Thus, it can be more readily tested as a
radiosensitizer for GBMs and other solid tumors in the clinic. Further
preclinical evaluation is warranted regarding the effects of NVP-
BEZ235 in combination with chemotherapy or radiation in mouse
tumor models of GBMs and other cancers.
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Table W1. Dilutions of Primary and Secondary Antibodies for Western Blot Analysis and IF.
Antibody Source Western IF
phospho-Akt(S473) Cell Signaling 1:1000
Akt Cell Signaling 1:1000
phospho-Chk2(T68) Cell Signaling 1:1000
phospho-p53(S15) Cell Signaling 1:1000
phosphoS6(S235/236) Cell Signaling 1:500
actin Sigma 1:1000
ATM Sigma 1:1000
Rad51 Santa Cruz 1:500
Cyclin A Santa Cruz 1:500
P53 Santa Cruz 1:1000







γH2AX Upstate 1:1000 1:2000
phospho-ATM(S1981) Genescript 1:1000 1:500
pDNA-PKcs (S2056) Abcam 1:1000 1:500
DNA-PKcs Thermo Fisher 1:1000
Ku80 Gift from Dr B. Chen 1:1000
HRP-conjugated secondary antibodies Biorad 1:3000
Alexa488/568-conjugated secondary antibodies Molecular Probes 1:1000
Table W2. Plating Efficiency of Human GBM Cell Lines after Treatment with Varying Concen-
trations of NVP-BEZ235.
Glioma Line Concentration of NVP-BEZ235 (nM)
0 10 50 100 500
U251 45.5% 45.3% 45.0% 39.8% 4.6%
U118 44.7% 43.6% 41.9% 40.1% 2.4%
LN18 37.6% 37.0% 36.7% 35.2% 10.7%
T98G 32.0% 31.0% 28.1% 27.0% 1.7%
LN229 49.7% 49.5% 47.9% 46.4% 5.7%
SF188 43.8% 42.7% 40.7% 34.0% 3.8%
Figure W1. Radiation survival of GBM cell lines after treatment with varying concentrations of NVP-BEZ235.
Figure W2. GBM cell lines were irradiated with 1 Gy of gamma rays after a 1-hour period of treatment with NVP-BEZ235, KU55933, or
NU7026 alone or with a combination of KU55933 and NU7026, as indicated. To quantify residual (unrepaired) DSBs, cells were immuno-
stained for 53BP1 foci at 24 hours after IR. Residual 53BP1 foci in irradiated cells were scored (average of 50 nuclei), and after subtracting
background (number of foci in mock-irradiated nuclei), average foci per nucleus were plotted against the indicated treatment conditions.
Figure W3. (A) AT5 cells were pretreated with NVP-BEZ235 and irradiated with 10 Gy of gamma rays. Autophosphorylation of DNA-PKcs
was assayed after 30 minutes by Western blot analysis with a α–phospho-DNA-PKcs (Ser2056) antibody. (B) M059J cells were pre-
treated with NVP-BEZ235 and irradiated with 10 Gy of gamma rays. Autophosphorylation of ATM was assayed after 30 minutes by
Western blot analysis with a α–phospho-ATM (Ser1981) antibody.
Figure W4. Inhibition of ATM kinase activity in irradiated human GBM lines after treatment with NVP-BEZ235 was analyzed by Western
blot analysis with α–phospho-ATM (Ser1981) antibody. Cells were irradiated (10 Gy) after 1 hour of drug treatment and harvested at
30 minutes after IR.
Figure W5. Inhibition of DNA-PKcs activity in irradiated human GBM lines after treatment with NVP-BEZ235 was analyzed by Western
blot analysis with α–phospho-DNA-PKcs (Ser2056) antibody. Cells were irradiated (10 Gy) after 1 hour of drug treatment and harvested at
30 minutes after IR.
Figure W6. (A) Inhibition of PI3K/Akt signaling in mock-irradiated or
irradiated human U87-EGFRvIII cells after treatment with 100 nM
NVP-BEZ235 was analyzed by Western blot analysis with α–phospho-
Akt (Ser473) antibody. Cells were irradiated (10 Gy) after 1 hour of
drug treatment and harvested at 30minutes after IR. (B) U87-EGFRvIII
cells were irradiated with 1 Gy of gamma rays after a 1-hour period
of NVP-BEZ235 treatment. Cells were immunostained for 53BP1 foci
at 0.5 and 24 hours after IR. 53BP1 foci were scored at 0.5 and
24 hours after IR (average of 50 nuclei), and after subtracting back-
ground (number of foci in mock-irradiated nuclei), average foci per
nucleus were plotted against the indicated times.
